• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clinical Trials

Delcath inks FDA deal for design of Phase III trial

January 20, 2016 By Fink Densford

Delcath (NSDQ:DCTH) said yesterday the company reached a special protocol assessment agreement with the FDA for the design of a Phase III trial of its Delcath Hepatic Delivery System and Melphalan Hydrochloride. The system is designed to treat patients with hepatic dominant ocular melanoma, the New York City-based company said. The company said the agreement acted as a […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Delcath Systems Inc.

Artificial pancreas from UVA heads to trials

January 4, 2016 By Fink Densford

A device developed at the University of Virginia School of Medicine which automatically monitors and regulates blood-sugar level in type 1 diabetes patients is slated to undergo 2 final clinical trials beginning early this year. UVA said it was hopeful that the long-term clinical trials would pave the way for FDA clearance of the ‘artificial pancreas’ […]

Filed Under: Clinical Trials, Drug-Device Combinations, Preclinical Trials Tagged With: University of Virginia Health System

pSivida surges on Medidur data

December 22, 2015 By Brad Perriello

Psivida (NSDQ:PSDV) shares surged today after the company said its Medidur drug-device combination met the primary endpoints in a Phase III clinical trial for treating posterior uveitis. Medidur uses the same injectable implant and drug as the Iluvien drug-device combo pSivida licensed to Alimera Sciences (NSDQ:ALIM) for treating diabetic macular degeneration. Iluvien won FDA approval in September […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: pSivida Corp.

Anika assigned to FDA's drug eval arm for Cingal approval

December 9, 2015 By Fink Densford

Anika Therapeutics today said the FDA’s Office of Combination Products assigned the company’s Cingal drug-combo to its Center for Drug Evaluation and Research arm to pursue premarket regulatory approval. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the company said. “While we […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Anika Therapeutics Inc.

Clearside Biomedical raises $14.4m, enrolls 1st patient in Phase III trial

December 8, 2015 By Fink Densford

Clearside Biomedical raised $14.4 million in a new round of equity financing, and said yesterday it enrolled the 1st patient in the Phase 3 Peachtree clinical trial of its CLS-TA for treating patients with macular edema associated with non-infectious uveitis. Clearside is developing CLS-TA triamcinolone acetonide to be delivered using its proprietary SCS microinjector for patients with […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations Tagged With: Clearside Biomedical

Transdermal Delivery Solutions launches Testagen pivotal trial

December 7, 2015 By Fink Densford

Transdermal Delivery Solutions said today the clinical trial of its Testagen Hypospray has entered its pivotal phase. The Testagen TDS is designed for testosterone replacement through transdermal absorption through a spray-on delivery system. “We are pleased to reach this milestone and expect our progress with the technology to accelerate rapidly from here. As with any […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Transdermal Delivery Solutions

Ocular Therapeutix launches another pivotal for Dextenza eye drug-device combo

November 24, 2015 By Brad Perriello

Ocular Therapeutix (NSDQ:OCUL) said today that it launched another pivotal trial for its Dextenza drug-device combination, its 2nd study of the treatment for an allergic conjunctivitis indication. Bedford, Mass.-based Ocular Therapeutix has had mixed results with Dextenza, formerly known as OTX-DP, which is designed to deliver sustained dosage of dexamethasone over 4 weeks, using a hydrogel plug […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Ocular Therapeutix

Intersect ENT touts sinus-implant study results

September 28, 2015 By Fink Densford

Intersect ENT (NSDQ:XENT) said today results from 3 clinical studies of its Propel, Resolve and Nova products showed positive results. The data was presented at the American Rhinologic Society’s annual meeting in Dallas. Each of the studies evaluated steroid releasing sinus implants placed in minimally invasive in-office procedures to reduce inflammation for patients with chronic […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

Intersect ENT's Propel study meets endpoint

August 17, 2015 By Fink Densford

Intersect ENT (NSDQ:XENT) said a new study of its Propel mini steroid-releasing sinus implant used after frontal sinus surgery met the primary endpoint in a clinical trial. The Propel device is already approved for use in the ethmoid sinuses, behind the bridge of the nose, in conjunction with sinus surgery to treat symptoms of chronic sinusitis, […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

Bellerophon plunges on failed cardiac implant trial

July 27, 2015 By Brad Perriello

Bellerophon Therapeutics (NSDQ:BLPH) said today that its bioabsorbable cardiac matrix failed to meet both the primary and secondary endpoints in a 303-patient clinical trial, sending its share price down nearly -63% today. BCM is a liquid medical device injected into the coronary artery leading to the damaged area of a heart, and is designed for use after […]

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Bellerophon Therapeutics

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 85
  • Go to page 86
  • Go to page 87
  • Go to page 88
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS